Skip to main content
Contact Us
Subscribe
E-Edition
96°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.32
+0.01 (+0.01%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
71
72
Next >
Drivers And Stock Pickers
February 13, 2024
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.
Via
Talk Markets
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
February 12, 2024
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
Via
Benzinga
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
February 02, 2024
Via
Benzinga
Merck & Co's Earnings: A Preview
January 31, 2024
Via
Benzinga
How Is The Market Feeling About Merck & Co?
January 30, 2024
Via
Benzinga
Why the quality investor may take a look at MERCK & CO. INC. (NYSE:MRK).
January 30, 2024
Why MERCK & CO. INC. (NYSE:MRK) Deserves Consideration as a Quality Investment.
Via
Chartmill
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
February 08, 2024
Investors are still excited about obesity treatments and weight-management drugs.
Via
The Motley Fool
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
February 05, 2024
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024."
Via
Benzinga
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
February 05, 2024
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued.
Via
Chartmill
7 Mutual Funds That Will Outperform in Any Market
February 03, 2024
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds.
Via
InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
February 02, 2024
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Merck Stock Rocketed Nearly 5% Skyward Today
February 01, 2024
The company reported healthy sales growth and proffered encouraging guidance to boot.
Via
The Motley Fool
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
Merck (MRK) Q4 2023 Earnings Call Transcript
February 01, 2024
MRK earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
February 01, 2024
Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
February 01, 2024
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024.
Via
Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February.
Via
Benzinga
Merck Reports A Surprise Profit As Keytruda Sales Continue On Their Warpath
February 01, 2024
Analysts expected an 11-cent per-share loss from Merck in the fourth quarter. But the company came out ahead.
Via
Investor's Business Daily
Earnings Scheduled For February 1, 2024
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Powell Dubious On March Cut, Markets Slide
January 31, 2024
Markets pulled back from their steady trading levels today once Fed Chair Jerome Powell, speaking at his press conference following the latest Fed meeting
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
January 29, 2024
Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive optimism.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.